Ostheimer Christian, Bache Matthias, Güttler Antje, Reese Thomas, Vordermark Dirk
Department of Radiation Oncology, Martin Luther University Halle-Wittenberg, Klinik und Poliklinik für Strahlentherapie, Martin Luther Universitaet Halle-Wittenberg, Ernst-Grube-Strasse 40, 06097 Halle (Saale), Germany.
BMC Cancer. 2014 Nov 21;14:858. doi: 10.1186/1471-2407-14-858.
Circulating baseline levels of the plasma-protein osteopontin (OPN) have been suggested as a prognostic indicator in chemotherapy and surgery for lung cancer. However, the role of this hypoxia-related protein in radiotherapy of lung cancer is unclear. We previously demonstrated the prognostic effect of baseline OPN plasma levels which was increased by co-detection with other hypoxia-related proteins in the radical radiotherapy of non-small-cell lung cancer (NSCLC). This prospective clinical study investigated whether serial OPN measurements during and after curative-intent radiotherapy for NSCLC provide additional or superior prognostic information.
Sixty-nine patients with inoperable NSCLC were prospectively enrolled (55 M0, 14 M1). OPN plasma levels were measured before (t0), at the end (t1) and four weeks after radiotherapy (t2) by ELISA, compared between M0 and M1 patients and correlated with clinicopathological parameters. OPN levels were monitored over time and correlated with prognosis in M0-stage patients treated by radical 66-Gy radiotherapy ± chemotherapy.
Pre-treatment OPN levels were associated with T stage (p = .03), lung function (p = .002), weight loss (p = .01), tumor volume (p = .02) and hemoglobin concentration (p = 04). M1 patients had significantly elevated OPN levels at all time points (p < .001). Patients with increasing OPN levels after radiotherapy had inferior freedom from relapse (p = .008), overall survival (p = .004) and disease-free survival (p = .001) compared to patients with stable or decreasing OPN levels. The risk of relapse in patients with increasing or stable OPN levels after radiotherapy was increased by a factor of 2.9 (p = .01). Patients with increasing post-treatment OPN levels had a 3.1-fold increased risk of death (p = .003). In an exploratory multivariate model, post-treatment OPN level changes but not absolute baseline OPN levels remained an independent prognostic factor for overall survival (p = .002) with a 3.6-fold increased risk of death, as well as N stage (p = .006).
Our results suggest that OPN level changes over time, particularly post-treatment, may yield additional prognostic information in curative-intent radiotherapy of NSCLC.
血浆蛋白骨桥蛋白(OPN)的循环基线水平被认为是肺癌化疗和手术中的一种预后指标。然而,这种与缺氧相关的蛋白在肺癌放疗中的作用尚不清楚。我们之前证明了基线OPN血浆水平在非小细胞肺癌(NSCLC)根治性放疗中与其他缺氧相关蛋白联合检测时的预后作用。这项前瞻性临床研究调查了在NSCLC根治性放疗期间及之后连续测量OPN是否能提供额外或更好的预后信息。
前瞻性纳入69例无法手术的NSCLC患者(55例M0,14例M1)。通过酶联免疫吸附测定法(ELISA)在放疗前(t0)、结束时(t1)和放疗后四周(t2)测量OPN血浆水平,比较M0和M1患者之间的水平,并与临床病理参数相关联。对M0期接受66 Gy根治性放疗±化疗的患者,随时间监测OPN水平并与预后相关联。
治疗前OPN水平与T分期(p = 0.03)、肺功能(p = 0.002)、体重减轻(p = 0.01)、肿瘤体积(p = 0.02)和血红蛋白浓度(p = 0.04)相关。M1患者在所有时间点的OPN水平均显著升高(p < 0.001)。与OPN水平稳定或下降的患者相比,放疗后OPN水平升高的患者复发自由度较低(p = 0.008)、总生存期(p = 0.004)和无病生存期(p = 0.001)较差。放疗后OPN水平升高或稳定的患者复发风险增加2.9倍(p = 0.01)。治疗后OPN水平升高的患者死亡风险增加3.1倍(p = 0.003)。在一个探索性多变量模型中,治疗后OPN水平变化而非绝对基线OPN水平仍然是总生存期的独立预后因素(p = 0.002),死亡风险增加3.6倍,以及N分期(p = 0.006)。
我们的结果表明,OPN水平随时间的变化,特别是治疗后,可能在NSCLC根治性放疗中产生额外的预后信息。